ArticleScientific reports2026
The incidence and clinical variables associated with new and new persistent benzodiazepine use after admission to internal medicine: a retrospective study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to describe the epidemiology of new and new persistent benzodiazepine (BZD) use following admissions to internal medicine and its relationship with patient and admission characteristics. Retrospective study that including all admissions of patients 18 years and older to Landspítali - The National University Hospital of Reykjavík, Iceland, between 2010 and 2020. BZD-naïve patients in the year preceding admission were classified into patients with new BZD use (filling one or more BZD prescriptions within 90 days of discharge), and new persistent use (filling a second prescription between 90 and 180 days). Among 54,844 eligible admissions, 6.3% (3471/54,844) initiated new use, and of those 39.4% (95% CI 37.8-41.0) developed new persistent use. Female sex and admission to several specialties, including cardiology, gastroenterology, pulmonology, neurology, rheumatology, hematology, oncology, or palliative care were associated with an increased risk of initiating new BZD use compared with general medicine (reference group). Medium and high frailty risk was associated with reduced odds of new use. Among patients who initiated new use, the risk of initiating new persistent BZD use was higher in female patients and patients with underlying COPD as well as patients admitted to cardiology, gastroenterology, pulmonology, geriatrics, hematology, or oncology services. The incidence of new BZD use following admissions to internal medicine in Iceland is high and a large portion of patients who initiate new use transition to new persistent use. This highlights the need for strategies to reduce the likelihood of new BZD use and reduce the risk of unintended transition of new persistent BZD use to ensure appropriate short-term BZD use. Further research is needed to understand the drivers of specialty-level variation in post-discharge BZD dispensing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.